期刊:The European respiratory journal [European Respiratory Society] 日期:2020-09-07卷期号:: 236-236被引量:2
标识
DOI:10.1183/13993003.congress-2020.236
摘要
Background: House dust mite (HDM) sublingual immunotherapy (SLIT) has demonstrated efficacy in clinical trials of patients with asthma. Type 2 inflammation is a characteristics of respiratory allergic disease, but its relationship to SLIT remain unclear. Aims and Objective: We evaluate the association between clinical outcomes with pulmonary function and type 2 biomarkers in before and after HDM SLIT. Methods: One hundred twelve asthmatic patients with rhinitis sensitized to HDM were randomized to add-on 6 standardized quality (SQ)-HDM SLIT to pharmacotherapy or pharmacotherapy alone for 48 weeks. At baseline and end of study, type 2 biomarkers, blood eosinophils, serum IgE, serum periostin and fractional exhaled nitric oxide (FeNO), and spirometry and clinical symptoms were measured. Results: SLIT demonstrated a significant reduction of serum IgE (p<0.05), serum periostin (p<0.001), FeNO (p<0.01), and improvement of FEV1 (p<0.001) and clinical symptom scores, when compared to pharmacotherapy. The change in FEV1 correlated with the changes in serum periostin (r=0.696, p<0.001) and the changes in FeNO (r=0.682, p<0.001). The independent predictor of improvement in airflow limitation were change in serum periostin (p=0.013) and FeNO (p=0.038). Conclusions: These findings suggest that adding HDM SLIT to pharmacotherapy reduces type 2 biomarkers, serum periostin and FeNO, and lead to a beneficial effect of allergic airway disease.